<DOC>
	<DOCNO>NCT00151710</DOCNO>
	<brief_summary>Congenital adrenal hyperplasia , autosomal recessive condition , mainly cause mutation gene 21-hydroxylase treated glucocorticoid slightly supraphysiological dose . Adult patient seem characterize insulin resistance , may cause glucocorticoid and/or accompany obesity . The hypothesis study pioglitazone improve insulin sensitivity correlate cardiovascular risk factor specific group patient . This tested randomized , placebo-controlled , cross-over trial ; insulin sensitivity quantify euglycemic hyperinsulinemic clamp study .</brief_summary>
	<brief_title>Effects Pioglitazone Congenital Adrenal Hyperplasia</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Adrenal Hyperplasia , Congenital</mesh_term>
	<mesh_term>Adrenogenital Syndrome</mesh_term>
	<mesh_term>Adrenocortical Hyperfunction</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>biochemical genetically proven congenital adrenal hyperplasia stable corticosteroid replacement 3 month age &lt; 18 year inability give inform consent significant cardiovascular disease , define myocardial infarction stroke , six month precede study significant renal disease , GFR &lt; 30 ml/min significant liver disease , define 3 time upper limit normal value alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) pregnancy mental disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2007</verification_date>
</DOC>